Do you want to link to this External Website and leave Amgen.nl?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Netherlands takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.


Wilt u deze Externe Website bezoeken en Amgen.nl verlaten?

U verlaat nu de website van Amgen Nederland. Amgen Nederland draagt geen verantwoordelijkheid voor, en oefent geen controle uit, over de organisaties, meningen or juistheid van de informatie van deze server of website.

Inflammatory diseases

A physician may prescribe AMGEVITA for the treatment of various inflammatory diseases. AMGEVITA contains the active ingredient adalimumab.

AMGEVITA is a drug that inhibits the inflammatory process in different inflammation diseases. The active ingredient, adalimumab, is a human monoclonal antibody produced by cultured cells. Monoclonal antibodies are proteins that recognize and bind to other unique proteins. Adalimumab binds to a specific protein (tumor necrosis factor or TNFα), which is present to an increased extent in various inflammatory diseases.

Your physician may prescribe AMGEVITA for the treatment of inflammatory diseases such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, ankylopoetics spondylitis, axial spondylarthritis without radiographic evidence of spondylitis ankylopoetica, arthritis psoriatica, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis and non-infectious uveitis affecting the back of the eye.

Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.